We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Benign Hematology

Journal Scan / Research · August 24, 2020

Ruxolitinib as a Front-Line Therapy for Children With Secondary Hemophagocytic Lymphohistiocytosis

Haematologica

 

Additional Info

Haematologica
A Pilot Study of Ruxolitinib as a Front-Line Therapy for 12 Children With Secondary Hemophagocytic Lymphohistiocytosis
Haematologica 2020 Jul 30;[EPub Ahead of Print], Q Zhang, A Wei, HH Ma, L Zhang, HY Lian, D Wang, YZ Zhao, L Cui, WJ Li, Y Yang, TY Wang, ZG Li, R Zhang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading